cember 31, 2007. The decrease in revenue was primarily due to a decrease in the number of contracts and related contract values of active clinical studies being conducted in the U.S. offset by an increase in revenues generated by our European operations, which was due in part to favorable foreign currency fluctuations. For the year, European operations represented 74% of net revenues and U.S. operations represented 26% of net revenues.
Direct expenses for the year ended December 31, 2008 were $21.3 million, or 70.6% of net revenue, compared to $20.2 million, or 64.0% of net revenue, for the year ended December 31, 2007 and included approximately $1.0 million in foreign currency fluctuations absorbed by the Company's European operations. SG&A expenses for 2008 were $14.1 million, or 46.6% of net revenue, compared to $12.4 million, or 39.1% of net revenue, for 2007. Of the $1.7 million increased in SG&A, approximately $900,000 was non-recurring transaction costs attributable to the Prologue and Linkcon transactions that were terminated during the third quarter of 2008. Excluding non-recurring transaction costs, SG&A would have decreased by $100,000 in 2008 compared to 2007 and would have represented approximately 40.6% of net revenue.
Depreciation and amortization expense for 2008 declined to $1.7 million compared to $2.6 million for the 2007, primarily as a result of a reduction in the amount of amortization related to the intangible assets acquired from the Remedium acquisition.
The Company reported a net loss for the twelve months ended December 31, 2008 of $21.1 million, or $(1.02) per diluted share, as compared to a net loss of $2.8 million, or $(0.14) per diluted share for the twelve months ended December 31, 2007. Included in the results is a non-cash $14.4 million, or ($0.70) per share, asset impairment charge related to the Company's intangible assets, which includes a $1.9 million non-cas
'/>"/>
SOURCE Encorium Group, Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related medicine news :1.
Encorium Announces Receipt of Letter from Nasdaq Regarding its 2008 Form 10-K Filing2.
Encorium Appoints Shahab Fatheazam to its Board of Directors3.
Universal Health Services, Inc. Reports 17% Increase in 2009 First Quarter Earnings from Continuing Operations Per Diluted Share4.
Hanger Orthopedic Group, Inc. Reports $0.14 EPS on 26.6% Increase in Net Income for the First Quarter 20095.
Remuda Ranch Reports Eating Disorders on the Rise Among Elderly6.
HCA Reports First Quarter 2009 Results7.
Recent Study Disproves General Hospitals Ongoing Criticism of Physician Owned Hospitals, Shows Little to No Effect on General Hospitals Business, Reports Physician Hospitals of America8.
Neovasc Inc. Reports Year 2008 Financial Results9.
NBTY Reports Second Quarter Results10.
Statement from USPA Exec. Dir. on News Reports of Florida Pharmacy Admission of Error in the Medicine Dispensed to the Horses Who Died on Sunday11.
Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65.